A Drug to Protect Muscle

If losing lean tissue is the main objection to these drugs, the pharmaceutical answer is a second drug that blocks it. Apitegromab targets myostatin — the signal that limits muscle growth — and a randomized trial tested it alongside tirzepatide. The authors conclude it was well tolerated and effective in preserving lean mass.^[1]

What was tested

A double-blind, placebo-controlled proof-of-concept study with 51 participants per arm, all receiving tirzepatide. Apitegromab concentrations and total latent myostatin — the marker showing the drug is doing what it is designed to do — both rose over time and plateaued at around 16 weeks.^[1]

Adverse events occurred in 76% of apitegromab participants and 71% on placebo. Serious adverse events were balanced: one participant in each arm.^[1]

Why a drug, when training already works

This is the question worth holding onto. Resistance training is the intervention with randomized evidence for changing what you lose — it cut the lean share of weight lost from roughly a quarter to 17.5% in a meta-analysis of 20 trials, covered in lean mass, drug versus dieting. It costs nothing and has no side effects worth the name.

There are real answers to that. Some people cannot train — disability, joint disease, or the sheer difficulty of starting when mobility is already limited. And adherence to exercise is famously poor, which is precisely the problem a drug solves. A pharmacological option is not a substitute for training so much as a fallback for people for whom training is not available.

The intervention with the best evidence is free. The one attracting investment is not. Both facts are worth holding at once.

And whether mass is the right target at all

Every drug in this category aims at lean mass, because mass is what a scan measures. What people actually need is function, and the two do not move together as reliably as the framing suggests.

We have covered a study where psoas muscle volume fell 9.3% while chair-rise time and walking speed both improved, and another where handgrip strength rose 4.5 kg over a year while sarcopenic obesity fell from 49% to 33% — in handgrip strength. A muscle-preservation drug that protected mass without improving function would be treating the measurement rather than the problem.

That is not an argument against developing one. It is an argument for insisting that the phase 3 program measures what people can do, and not only what the scan says.